Gilead Sciences funded FHCSD to implement a pragmatic quality-improvement randomized controlled trial. This study tested the effectiveness of a simplified HCV algorithm with integrated care (including the offer of buprenorphine prescriptions and abscess care), in a street-based mobile clinic setting among PWID, in increasing treatment initiation and retention rates. Rates of HCV treatment initiation and retention were compared between patients offered HCV care in a mobile clinic versus those who are linked to a community clinic’s current practice of usual care, which includes comprehensive patient navigation.
Completed